ImmunityBio, Inc. (IBRX) shares skyrocketed nearly 29% today to $3.89 as investors reacted to a dual-catalyst event involving international regulatory wins and explosive revenue growth. The stock's performance on January 15, 2026, marks a significant breakout, trading near the high end of its 52-week range of $1.83 to $4.27.
| Current Price | $3.89 |
| Daily Change | +28.64% 🟢 |
| Day Range | $3.08 – $3.99 |
| 52-Week Range | $1.83 – $4.27 |
This massive rally was ignited as market forces reacted to two major announcements: the landmark approval of the company’s flagship drug, ANKTIVA, by the Saudi Food and Drug Authority (SFDA) and preliminary full-year 2025 financial results showing a 700% surge in net product revenue. The news has propelled the stock to a one-month gain of over 70%.
Key Takeaways
- IBRX stock jumped nearly 29% following key regulatory approvals in Saudi Arabia.
- Preliminary 2025 revenue hit $113 million, representing a 700% year-over-year increase.
- ANKTIVA received the world’s first approval for metastatic non-small cell lung cancer (NSCLC) in Saudi Arabia.
- Positive clinical trial data showed a median overall survival of over 16 months for responders.
- ImmunityBio significantly outperformed its biotech peers and the industry average today.
What Triggered ImmunityBio (IBRX)'s 28% Stock Surge Today?
The primary driver behind today's surge is a combination of commercial momentum and regulatory expansion. According to company reports, preliminary net product revenue for 2025 reached approximately $113.0 million.
This massive growth was fueled by a 750% increase in ANKTIVA unit sales volume throughout the year. Financial data indicates that the stock specifically gained 7% immediately following the Saudi approval news before continuing its upward trajectory.
The momentum was further bolstered by premarket trading activity where shares rose as much as 17% early Thursday morning.
ANKTIVA Gains Key Saudi Regulatory Approvals for Lung & Bladder Cancers
In a historic move, the Saudi FDA granted accelerated approval for ANKTIVA in combination with checkpoint inhibitors for metastatic non-small cell lung cancer. This is the first global approval for this specific indication and the first for its subcutaneous formulation.
Dr. Patrick Soon-Shiong, ImmunityBio’s Founder and Executive Chairman, noted the approval marks a landmark for IL-15 superagonists. The Saudi regulator also approved ANKTIVA for patients with BCG-unresponsive non-muscle invasive bladder cancer.
ImmunityBio plans to establish a regional office in Saudi Arabia and has partnered with Biopharma Cigalah to commercialize the treatment across the Middle East and North Africa. CEO Richard Adcock emphasized that this addresses a large and growing incidence of cancers in the region.
ImmunityBio Reports 700% Revenue Jump and Strong ANKTIVA Sales Momentum
The financial side of today's news is equally robust. For the fourth quarter of 2025, ImmunityBio reported preliminary net product revenue of $38.3 million.
This represents a 20% increase over the previous quarter and a staggering 431% jump compared to the fourth quarter of 2024. The company ended the year with an estimated $242.8 million in cash, cash equivalents, and marketable securities.
This liquidity provides a foundation for the company as it ramps up its commercial infrastructure. CEO Richard Adcock stated the results reflect the accelerating adoption of ANKTIVA and the continued execution of the company's commercial strategy.
Positive Clinical Trial Data Bolsters ANKTIVA's Therapeutic Potential
Beyond the financials, clinical results from the QUILT-2.023 and QUILT-3.055 trials have provided a scientific tailwind. The data demonstrated that ANKTIVA acts as a lymphocyte-stimulating agent, leading to noteworthy immune restoration.
In studies of second and third-line NSCLC, responders saw a median overall survival of 16.2 months, compared to 11.8 months for non-responders. The trials also highlighted that patients with higher immune competence reached an overall survival of 21.1 months.
These figures compare favorably to historical chemotherapy survival rates, which typically range between 7 and 9 months. Dr. Soon-Shiong suggested these results support a potential paradigm shift toward restoring immune competence to extend life.
How Does ImmunityBio (IBRX) Compare to its Biotech Peers?
ImmunityBio's nearly 29% gain today stands in stark contrast to a broader decline in the biotechnology sector, standing out among highly volatile small cap stocks in the biotech space. While IBRX soared, the industry average change today was a decrease of over 3%.
Most of the company's peers also struggled during the session. For context, Structure Therapeutics (GPCR) remained essentially flat, while Inhibrx Biosciences (INBX) fell about 3%.
Other peers like RAPT Therapeutics (RAPT) and Anbio Biotechnology (NNNN) saw deeper declines of 6% and nearly 8%, respectively. This divergence highlights that today's movement in IBRX is a stock-specific reaction to its own positive catalysts rather than a sector-wide trend.
| Company | Symbol | Daily Change | Market Cap |
|---|---|---|---|
| Structure Therapeutics | GPCR | +0.04% | – |
| Inhibrx Biosciences | INBX | -3.07% | – |
| RAPT Therapeutics | RAPT | -6.00% | – |
| Anbio Biotechnology | NNNN | -7.70% | – |
| Celldex Therapeutics | CLDX | -3.30% | – |
| PTC Therapeutics | PTCT | -1.48% | – |
| Immunocore Holdings | IMCR | -1.52% | – |
| Industry Average | – | -3.29% | – |
| ImmunityBio | IBRX | +28.64% | – |
Market Cap data not available for these entities.
What Should IBRX Investors Watch Next?
Moving forward, investors should monitor the confirmation of these preliminary results through audited financial statements. Investors often use the best stock analysis apps to monitor these regulatory milestones and financial audits.
Additionally, the accelerated approval in Saudi Arabia for NSCLC is conditional and requires confirmation from the ongoing randomized ResQ 201A trial.
| Time Period | Price Change | Performance |
|---|---|---|
| 1 Month | +70.27% | 🟢 |
| 3 Months | +46.51% | 🟢 |
| 6 Months | +33.57% | 🟢 |
| 1 Year | +62.93% | 🟢 |
The company is also looking toward the completion of the Phase 2b QUILT-2.005 trial, which is currently projected for the second quarter of 2026. With the immuno-oncology market projected to grow from $35 billion to over $185 billion by 2035, ImmunityBio's ability to maintain its sales momentum will be critical.
The Bottom Line
ImmunityBio’s performance today reflects a company successfully transitioning from clinical development to significant commercial scale. The combination of triple-digit revenue growth and world-first regulatory approvals provides a strong catalyst for the stock's current momentum.
| 🟢 Bull Case | 🔴 Bear Case |
|---|---|
| • 700% YoY net product revenue growth | • Financial figures are preliminary & unaudited |
| • Global-first Saudi approval for NSCLC | • NSCLC approval is conditional on future trials |
| • Strong cash position (~$242.8M) | • Missing specific analyst price targets |
| • Positive OS data (16.2mo vs 11.8mo) | • Potential for high volatility in small-cap biotech |
However, some caution remains necessary as the company’s financial figures are preliminary and one of its key approvals is conditional. Investors will need to see if the sales volume growth of 750% seen in 2025 can be sustained during Middle East expansion.
